ArriVent Secures $312.8M Cash Runway Through 3Q 2027, Phase 3 Data Due Mid-2026
ArriVent ended 2025 with $312.8 million in cash and investments, funding operations into 3Q 2027. The company’s Phase 3 pivotal studies for firmonertinib in EGFR exon 20 insertions and PACC mutant NSCLC are underway, with topline data expected mid-2026 and ADC program ARR-217 now in Phase 1.
1. Financial Results
ArriVent reported cash and investments of $312.8 million as of December 31, 2025, projecting funding operations into the third quarter of 2027. Net cash used in operations was $160.6 million in 2025 versus $70.2 million in 2024, while R&D expenses rose to $153.4 million from $79.0 million.
2. Firmonertinib Phase 3 Progress
During 2025, ArriVent advanced two pivotal Phase 3 programs for firmonertinib: the FURVENT trial in first-line NSCLC EGFR exon 20 insertion mutations completed enrollment and holds FDA Breakthrough Therapy designation, and the ALPACCA study in first-line EGFR PACC mutant NSCLC dosed its first patient, with topline data expected mid-2026.
3. ADC Pipeline Advancement
The ADC pipeline progressed with ARR-217, a CDH17-targeted candidate in Phase 1 dose escalation for gastrointestinal cancers after FDA IND clearance and first patient dosing in March 2026. An IND filing for the ARR-002 ADC program is planned in the first half of 2026.